Christophe Mendoza

Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial).

O. Tillement, M. Loeffler, P. Pauwels, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol

O. Tillement, J. Arnaud, S. Grand, 2019, BMJ Open.

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

C. Aspord, P. Coulie, B. Dréno, 2020, Oncoimmunology.

Evidence for Post-Translational Processing of Vascular Endothelial (VE)-Cadherin in Brain Tumors: Towards a Candidate Biomarker

J. Lebas, S. Boccard, J. Quesada, 2013, PloS one.

High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT)

D. Pezet, J. Quesada, L. Mineur, 2016, Annals of Surgical Oncology.